Global Alpha Capital Management Ltd. Has $32.01 Million Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Global Alpha Capital Management Ltd. boosted its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 536,450 shares of the specialty pharmaceutical company’s stock after purchasing an additional 9,500 shares during the period. ANI Pharmaceuticals comprises 2.1% of Global Alpha Capital Management Ltd.’s holdings, making the stock its 23rd largest position. Global Alpha Capital Management Ltd.’s holdings in ANI Pharmaceuticals were worth $32,005,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Innealta Capital LLC acquired a new stake in ANI Pharmaceuticals in the 2nd quarter valued at about $65,000. Ridgewood Investments LLC bought a new position in ANI Pharmaceuticals in the 2nd quarter valued at about $85,000. SG Americas Securities LLC bought a new position in ANI Pharmaceuticals in the 1st quarter valued at about $106,000. XTX Topco Ltd bought a new position in ANI Pharmaceuticals in the 2nd quarter valued at about $207,000. Finally, O Shaughnessy Asset Management LLC bought a new position in ANI Pharmaceuticals in the 1st quarter valued at about $218,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ANIP has been the topic of several research analyst reports. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Piper Sandler initiated coverage on shares of ANI Pharmaceuticals in a report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Raymond James raised their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a report on Wednesday, September 18th. Finally, Truist Financial raised their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 22nd. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $77.33.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP opened at $55.69 on Wednesday. The company’s 50 day simple moving average is $58.34 and its 200 day simple moving average is $61.11. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -101.25 and a beta of 0.71. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. ANI Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. The business had revenue of $148.30 million for the quarter, compared to analysts’ expectations of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same period last year, the firm posted $1.05 earnings per share. As a group, research analysts predict that ANI Pharmaceuticals, Inc. will post 3.5 EPS for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.